| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Second Department of Internal Medicine, Nagasaki University School of Medicine; and the Department of Hygiene, Miyazaki Medical College, Japan
2 From the Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan
The efficacy of low dose long-term erythromycin (EM) therapy in the treatment of chronic lower respiratory tract disease, including diffuse panbronchiolitis (DPB), has been reported, but its therapeutic mechanism is still unclear. In 13 patients receiving oral EM therapy the accumulation of neutrophils in bronchoalveolar lavage (BAL) fluid was significantly reduced (p<0.05), this reduction corresponds with an improvement in clinical symptoms. We sought to determine whether neutrophil chemotactic activity (NCA) in lavage fluid obtained from these 13 patients with DPB would respond to EM therapy. Pretreatment NCA in all patients was significantly elevated compared with levels in normal healthy nonsmoking volunteers (p<0.001), and the level was greatly reduced after EM therapy (p<0.001). In addition, this reduction correlated with increased percentages of neutrophils in the BAL fluid (r=0.737, p<0.01). Gel-filtration chromatography was also performed to characterize chemotactic factors. Pre-EM treatment BAL fluid revealed four NCA peaks (about molecular weight 15,000, 8,000, 1,500, and 300 daltons) in the elution profile, and chemotactic activity was reduced in all areas after EM therapy. These findings indicate that NCA in lavage fluid from patients with DPB consists of various components. Although it was not clear which component is predominantly affected, these results indicate that EM may inhibit the migration of neutrophils to inflammatory sites by reducing the intrapulmonary chemotactic gradient, thus, ultimately reducing pulmonary inflammation.
Key Words: bronchoalveolar lavage fluid • diffuse panbronchiolitis • erythromycin • neutrophil chemotactic factor
Submitted on November 5, 1993
Accepted on January 26, 1994
This article has been cited by other articles:
|
|
 |
|
  V. Poletti, G. Casoni, M. Chilosi, and M. Zompatori Diffuse panbronchiolitis Eur. Respir. J., October 1, 2006; 28(4): 862 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Schultz Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis J. Antimicrob. Chemother., July 1, 2004; 54(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ryu, J. L. Myers, and S. J. Swensen Bronchiolar Disorders Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1277 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jones, H. Elphick, E. Pettitt, M.L. Everard, and G.S. Evans Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase Eur. Respir. J., June 1, 2002; 19(6): 1136 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ishii, N. Keicho, S. Teramoto, A. Azuma, S. Kudoh, Y. Fukuchi, Y. Ouchi, and T. Matsuse Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis Eur. Respir. J., November 1, 2001; 18(5): 753 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tsurita, M. Kurokawa, M. Imakita, Y. Fukuda, Y. Watanabe, and K. Shiraki Early Augmentation of Interleukin (IL)-12 Level in the Airway of Mice Administered Orally with Clarithromycin or Intranasally with IL-12 Results in Alleviation of Influenza Infection J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 362 - 368. [Abstract] [Full Text]
|
|
|
|
|
|
T. Yoshii, H. Nishimura, T. Yoshikawa, S. Furudoi, A. Yoshioka, I. Takenono, Y. Ohtsuka, and T. Komori Therapeutic possibilities of long-term roxithromycin treatment for chronic diffuse sclerosing osteomyelitis of the mandible J. Antimicrob. Chemother., May 1, 2001; 47(5): 631 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sassa, Y. Mizushima, T. Fujishita, R. Oosaki, and M. Kobayashi Therapeutic Effect of Clarithromycin on a Transplanted Tumor in Rats Antimicrob. Agents Chemother., January 1, 1999; 43(1): 67 - 72. [Abstract] [Full Text]
|
|
|
|
|
|
M. Duong, M. Simard, Y. Bergeron, N. Ouellet, M. Côté-Richer, and M. G. Bergeron Immunomodulating Effects of HMR 3004 on Pulmonary Inflammation Caused by Heat-Killed Streptococcus pneumoniae in Mice Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3309 - 3312. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. W T Tsang, C. G C Ooi, M. S M Ip, W.-k. Lam, H. Ngan, E. Y T Chan, B. Hawkins, C.-s. Ho, R. Amitani, E. Tanaka, et al. Clinical profiles of Chinese patients with diffuse panbronchiolitis Thorax, April 1, 1998; 53(4): 274 - 280. [Abstract] [Full Text]
|
|
|
|
|
|
A. Azuma, T. Furuta, T. Enomoto, Y. Hashimoto, K. Uematsu, N. Nukariya, A. Murata, and S. Kudoh Preventive effect of erythromycin on experimental bleomycin-induced acute lung injury in rats Thorax, March 1, 1998; 53(3): 186 - 189. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
